Tag: Biosciences
NFL Biosciences: success of the capital increase
(CercleFinance.com) – NFL Biosciences announced on Friday that it had successfully completed its capital increase for an amount of more than three million euros. The biopharmaceutical company, which develops botanical…
NFL Biosciences raises some 3 million euros through capital increases – 04/11/2024 at 6:10 p.m.
(AOF) – NFL Biosciences announces that some 3 million euros will be raised in the form of capital increases. The biotech developing botanical medicines for the treatment of dependencies and…
NFL Biosciences raises around 3 million euros through capital increases
(AOF) – NFL Biosciences announces that some 3 million euros will be raised in the form of capital increases. The biotech developing botanical medicines for the treatment of dependencies and…
NFL Biosciences launches a fundraising of around 3 ME
By Alexandra Saintpierre Published on 04/11/2024 at 6:39 p.m. Photo credit © NissierPictures (Boursier.com) — NFL Biosciences…
Success of the NFL Biosciences operation with more than 3 million euros raised through a capital increase – 04/12/2024 at 07:45
Successful placement with professional investors with a very diversified base of international and French investors for an amount of €2.5 million. Sustained participation of individuals via the PrimaryBid platform with…
NFL BIOSCIENCES PROMOTES ITS STUDY RESULTS TO THE SCIENTIFIC AND PHARMACEUTICAL COMMUNITY – 04/02/2024 at 08:00
NFL BIOSCIENCES (Euronext Growth Paris – FR0014003XT0 – ALNFL), a biopharmaceutical company developing botanical drugs for the treatment of addictions, focuses on exploiting the promising scientific results of NFL-101, its…
NFL BIOSCIENCES: ACTIVITIES & ANNUAL RESULTS 2023 – 03/29/2024 at 5:45 p.m.
Promising results from the PRECESTO Phase 2a exploratory studySuccess of the study with the CEA on the mechanism of action of NFL-101CESTO II clinical study (phase 2b, ongoing) of drug…
NFL Biosciences will present its results at the SRNT congress – 02/13/2024 at 6:17 p.m.
(AOF) – NFL Biosciences announces that it has been selected by the SRNT (Society for Research on Nicotine & Tobacco) to present the results of the Precesto study at the…
NFL Biosciences will present its results at the SRNT congress
(AOF) – NFL Biosciences announces that it has been selected by the SRNT (Society for Research on Nicotine & Tobacco) to present the results of the Precesto study at the…
NFL BIOSCIENCES: FILING OF A PRE-IND APPLICATION WITH THE FDA IN THE UNITED STATES FOR NFL-301 DEDICATED TO THE REDUCTION OF ALCOHOL CONSUMPTION – 12/19/2023 at 08:00
NFL BIOSCIENCES (Euronext Growth Paris – FR0014003XT0 – ALNFL), a biopharmaceutical company developing botanical drugs for the treatment of dependencies and addictions, announces that it has today filed a pre-IND…
NFL BIOSCIENCES: ACTIVITIES & RESULTS OF THE 1ST HALF 2023 – 05/10/2023 at 7:00 p.m.
Promising results from the PRECESTO Phase 2a exploratory study: detailed analysisCESTO II clinical study (phase 2b, ongoing) of drug candidate NFL-101 for withdrawalsmoking: communication of results in July 2024Co-development of…
NFL BIOSCIENCES: PROMISING RESULTS OF THE PRECESTO CLINICAL STUDY REVEALING A LONG-LASTING EFFECT OF NFL-101 AND MODIFICATION OF THE COMMUNICATION STRATEGY OF THE RESULTS OF THE CESTO II STUDY – 09/25/2023 at 08:00
The PRECESTO clinical trial shows a clinically relevant reduction in smoking satisfaction in smokers not trying to quit with a more lasting effect than expected. The therapeutic potential of NFL-101…